Abstract:Purpose/Objective(s) After receiving dose-intensive chemotherapy and gross total resection (GTR), patients with high-risk neuroblastoma (HR-NB) are treated with adjuvant radiation therapy (RT) to the primary site, typically to a dose of approximately 21 Gy. This regimen is associated with excellent local control. However, in these young children, late toxicities to bone, pancreas, and other organs as well as second cancer risk are a major concern. After favorable results in a pilot trial using 18 Gy in 25 patients, we sought to prospectively evaluate local control with a further dose reduction to 15 Gy. Materials/Methods Eligible patients included those with HR-NB (as defined by the Children’s Oncology Group risk stratification schema) who have achieved a GTR of the primary site of disease after induction systemic therapy. Any patients with macroscopic residual disease at the primary site after surgery were excluded. Following surgery, patients were treated with 15 Gy to the primary site in 1.5 Gy fractions twice daily. The primary outcome of the trial was to assess the local failure (LF) rate, as determined by radiographic imaging. Gray’s test was used to compare the incidence of LF across MYCN status. Secondary outcomes included an assessment of event-free survival (EFS), overall survival (OS), and both acute (< 6 months) and late (≥ 6 months) toxicity, as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results A total of 53 patients were enrolled between 2018-2023 at a single institution. Median follow up from time of RT was 22 months (range = 4-65 months). Median age at the time of RT was 3.5 years (range = 0.8-10.9 years). Primary site was abdominal in 50 patients (94%) and mediastinal in 3 (6%). Forty-four patients (83%) received proton RT. Four patients experienced LF at the primary site of disease (crude risk 7.5%). These failures occurred 1, 3, 8, and 16 months after RT (median 5.5 months). The estimated risk of LF 2 years after RT was 8.4% (95% confidence interval = 2.6%-19%). The risk of LF was not significantly different between patients with MYCN-amplified disease (n = 28) versus those who had non-MYCN-amplified disease (n = 25) (P > 0.9). Six of the 53 patients died (11%); the median OS was not reached. There were 19 instances of any neuroblastoma progression (36%); median EFS was not reached. Of the 53 patients, 16 patients experienced acute toxicity, which included grade 1-2 fatigue, nausea, decreased appetite, diarrhea, and dermatitis. There were no toxicities above grade 2. There were no late toxicities of any grade observed in the cohort of patients, with current dates of follow up. Conclusion For patients with HR-NB who have a GTR of the primary site, reduced-dose RT of 15 Gy is associated with a 2-year LF rate of 8.4%, in line with published data after 21 Gy. The treatment was well-tolerated, with only grade 1-2 acute toxicities and no late toxicities. These data support continued use of 15 Gy for HR-NB. More follow-up is needed to verify a reduction in late effects.

Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results

Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series

Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies

Use of Pulsed Low–Dose Rate Radiotherapy in Refractory Malignancies

Radt-37. Proton Therapy Reirradiation For Recurrent Malignant Glioma: Prospective Analysis From The Proton Collaborative Group

Repeat peptide receptor radionuclide therapy in neuroendocrine neoplasms: A NET Center of Excellence experience.

Re-irradiation treatment regimens for patients with recurrent glioma - Evaluation of the optimal dose and best concurrent therapy

Efficacy and safety of PLDR-IMRT for the re-irradiation of recurrent NPC: A prospective, single-arm, multicenter trial

PENTEC Organ-Specific Report: Brain and Brain Stem Necrosis After Reirradiation for Recurrent Childhood Primary Central Nervous System Tumors: A PENTEC Comprehensive Review

Radt-17. Fractionated Reirradiation Of Recurrent Idh Wildtype Glioblastoma: Higher Reirradiaiton Dose And Safety

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy

Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity

Use of Cetuximab in Combination with Pulsed Reduced Dose-Rate Radiotherapy in a Patient with Recurrence of Nasopharyngeal Carcinoma in the Neck.

PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center

Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial

Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes

Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR)

Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescents

Hypofractionated re‐irradiation for diffuse intrinsic pontine glioma

Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma-Safety and outcomes

Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma